This study assessed the cumulative incidence of cardiovascular evens after zotarolimus eluting stent implantation. Individual studies often lack enough statistical power to show differences in low frequency adverse events. The Resolute zotarolimus eluting stent was evaluated across 10 prospective clinical trials designed with identical adverse events definitions. The Global Resolute clinical trial program...
Courtesy of Dr. Carlos Fava. Unprotected left main coronary artery (LMCA) angioplasty has become an important trend in the last few years. One of the most significant unresolved questions about it is whether one stent is better than two in distal lesions, and how is their progress after treatment. This study included 937 patients who...
The largest randomized trial in history found no difference in the primary endpoint of death and nonfatal infarction between current conventional stents and drug-eluting stents at over 5 years in patients with stable or unstable coronary disease. As expected, NORSTENT did find a difference in revascularization rates between both groups. This study presented at the...
Original Title: Incidence and Clinical Outcome of Stent Fractures on the Basis of 6555 Patients and 16482 Drug Eluting Stents From 4 Centers. Reference: Kan J et al. JACC Cardiovasc Interv. 2016 Jun 13;9(11):1115-23. Courtesy of Dr. Guillermo Migliaro. Stent fracture (SF) has been associated with instent restenosis (ISR), stent thrombosis (ST) and repeat revascularization...
Original Title: Stent Thrombosis with Drug Eluting Stents and Bioresorbable Scaffolds. Evidence from a Network Meta-Analysis of 147 trials. Reference: Kang S et al. J Am Coll Cardiol Intv 2016 doi 10.1016. Courtesy of Dr. Guillermo Migliaro. When treating heart disease, drug eluting stents (DES) have become essential for PCI. Its main advantage lies on...
Original Title: Left main stenting in Comparison with Surgical Revascularization 10-year outcomes of the (Left Main Coronary Stenting) LE MANS trial. Reference: Buszman P et al. J Am CollCardiolIntv. 2016;9(4):318-327. doi:10.1016/j.jcin.2015.10.044. Courtesy of Dr. Guillermo Migliaro. Long term outcomes of left main stenting are unknown. This study reports 10 year follow up outcomes of the LEMANS trial patients. The...
Original Title: Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations. Reference: Toru Naganuma et al. EuroIntervention 2016;11:989-995 Courtesy of del Dr. Santiago F. Coroleu. PCI involving in-stent restenosis (ISR), especially in coronary bifurcations, is associated with high rates of recurrent restenosis and the need for new revascularization. Although drug...
Original Title: Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial CME. Reference: Ricardo A. Costa et al. J Am Coll Cardiol Intv. 2016;9(1):51-64. The purpose of this study was to assess the efficacy and long...
Original Title: “Long-term outcomes of routine versus provisional T-stenting for de novo coronary bifurcation lesions: five-year results of the Bifurcations Bad Krozingen I study”. Authors: Miroslaw Ferenc, MD; Mohamed Ayoub, MD; Hans-Joachim Büttner, MD; Michael Gick, MD; Thomas Comberg, MD; Jürgen Rothe, MD; Christian M. Valina, MD; Willibald Hochholzer, MD; Franz-Josef Neumann, MD. Division of Cardiology and...
Original Title: Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. Reference: Stone, M.D. for the ABSORB III Investigators. N Engl J Med 2015;373:1905-1915. The ABSORB III is part of a series of randomized studies that test bioresorbable scaffolds in the clinical practice (ABSORB II, EVERBIO II, ABSORB Japan, and ABSORB IV). 2008 patients were randomized; 60% had...